The short answer
Trial names used in press coverage are frequently not registered acronyms. Searching ClinicalTrials.gov for REDEFINE 4 returns REDEFINE 1, 2 and 3 and never the trial itself, which is registered as NCT06131437 with no acronym at all.
Key facts
- REDEFINE 4 registration
- NCT06131437
- Registered acronym
- None
- Searching 'REDEFINE 4' returns
- REDEFINE 1, 2 and 3
- Reliable search
- Compound names, not trial names
- Site is a JS app
- Use the v2 API to read records
- Wrong NCT IDs found here
- Three, since corrected
Why trial names mislead
A programme name like REDEFINE or TRIUMPH is a sponsor's label for a family of studies, and individual members may or may not carry it as a registered acronym. REDEFINE 1, 2 and 3 do. The head-to-head against tirzepatide does not; its registry entry has no acronym field populated at all, so a name search cannot reach it.
What to search instead
Compound names and the comparison itself. Searching for the two drugs together returns the record immediately where the trial name fails. Then confirm identity from the official title, the enrolment number and the sponsor rather than from whichever entry appeared first.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Reading the record itself
ClinicalTrials.gov is a JavaScript application, so fetching the page often returns nothing useful. The v2 API returns structured data directly: an ordinary request for a study by its NCT number gives status, phase, enrolment, dates, allocation, masking, arms and primary outcome as plain fields.
The fields worth checking every time
Overall status, because trials change state. Enrolment, because reported figures drift. Allocation and masking, because open-label is a material limitation that press coverage omits. And the primary outcome text, which states what the trial actually set out to show. For NCT06131437 it reads as confirming non-inferiority, which is the whole context for what happened.
Why this site checks obsessively
Because three NCT identifiers published here were wrong, and one of them labelled TRIUMPH-1 pointed at an orforglipron trial, a different compound entirely. Every identifier now gets resolved against the registry before publication, and every trial referenced in this batch was pulled fresh from the API rather than recalled.
The check that takes ten seconds
Open the record. Read the official title. Confirm it names the compound you expect. A plausible-looking identifier from the right sponsor in the right format can still point at the wrong molecule, and reading the title is the step that catches it.
Frequently asked questions
Why can't I find REDEFINE 4 on ClinicalTrials.gov?
It has no registered acronym. Search the compound names instead; it is NCT06131437.
Why does fetching a ClinicalTrials.gov page return nothing?
It is a JavaScript application. The v2 API returns the same record as structured data.
Which fields matter most?
Status, enrolment, allocation and masking, and the primary outcome text, which states what the trial actually set out to show.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Research & Regulatory News articles
- Accelerated Approval Is a Conditional StatementApproval on a surrogate endpoint, with confirmatory evidence required afterwards. Why that is a genuinely different decision from a standard approval.
- What the MHRA Found in a Northampton WarehouseOctober 2025: tens of thousands of empty pens, raw ingredients and over 2,000 unlicensed retatrutide and tirzepatide pens ready for dispatch.
- The Scale of UK Medicines EnforcementAlmost 20 million doses and nearly £45m of illegal medicines seized in 2025, including more than 5,000 illegally traded GLP-1 products.
- The EMA Opinion on Oral Semaglutide for Weight ManagementOn 21 May 2026 the CHMP recommended adding oral tablets to Wegovy's authorisation in four strengths. What a positive opinion is, and what it is not.
- MARITIME: Where the Monthly Compound Is Being TestedMaridebart cafraglutide's Phase 3 programme spans obesity, sleep apnoea and heart failure - including a 5,056-participant cardiology trial.